Feasibility of gastric endoscopic submucosal dissection with continuous low-dose aspirin for patients receiving dual antiplatelet therapy.
Aged
Aged, 80 and over
Aspirin
/ administration & dosage
Clopidogrel
/ administration & dosage
Endoscopic Mucosal Resection
/ adverse effects
Feasibility Studies
Female
Gastric Mucosa
/ blood supply
Gastrointestinal Hemorrhage
/ epidemiology
Gastroscopy
/ adverse effects
Humans
Male
Middle Aged
Platelet Aggregation Inhibitors
/ administration & dosage
Postoperative Hemorrhage
/ epidemiology
Practice Guidelines as Topic
Retrospective Studies
Risk Factors
Stomach Neoplasms
/ pathology
Thrombosis
/ prevention & control
Treatment Outcome
Dual antiplatelet therapy
Endoscopic submucosal dissection
Low-dose aspirin
Postoperative bleeding
Thienopyridine
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
28 Jan 2019
28 Jan 2019
Historique:
received:
29
11
2018
revised:
19
12
2018
accepted:
09
01
2019
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
6
4
2019
Statut:
ppublish
Résumé
Endoscopic submucosal dissection (ESD) for gastric neoplasms during continuous low-dose aspirin (LDA) administration is generally acceptable according to recent guidelines. This retrospective study aimed to investigate the effect of continuous LDA on the postoperative bleeding after gastric ESD in patients receiving dual antiplatelet therapy (DAPT). To investigate the feasibility of gastric ESD with continuous LDA in patients with DAPT. A total of 597 patients with gastric neoplasms treated with ESD between January 2010 and June 2017 were enrolled. The patients were categorized according to type of antiplatelet therapy (APT). The postoperative bleeding rate was 6.9% (41/597) in all patients. Patients were divided into the following two groups: no APT ( The bleeding rate with continuous LDA in patients receiving DAPT was not statistically different from that with discontinuous LDA in patients receiving DAPT. Therefore, continuous LDA administration may be acceptable for ESD in patients receiving DAPT, although patients should be carefully monitored for possible bleeding.
Sections du résumé
BACKGROUND
BACKGROUND
Endoscopic submucosal dissection (ESD) for gastric neoplasms during continuous low-dose aspirin (LDA) administration is generally acceptable according to recent guidelines. This retrospective study aimed to investigate the effect of continuous LDA on the postoperative bleeding after gastric ESD in patients receiving dual antiplatelet therapy (DAPT).
AIM
OBJECTIVE
To investigate the feasibility of gastric ESD with continuous LDA in patients with DAPT.
METHODS
METHODS
A total of 597 patients with gastric neoplasms treated with ESD between January 2010 and June 2017 were enrolled. The patients were categorized according to type of antiplatelet therapy (APT).
RESULTS
RESULTS
The postoperative bleeding rate was 6.9% (41/597) in all patients. Patients were divided into the following two groups: no APT (
CONCLUSION
CONCLUSIONS
The bleeding rate with continuous LDA in patients receiving DAPT was not statistically different from that with discontinuous LDA in patients receiving DAPT. Therefore, continuous LDA administration may be acceptable for ESD in patients receiving DAPT, although patients should be carefully monitored for possible bleeding.
Identifiants
pubmed: 30700942
doi: 10.3748/wjg.v25.i4.457
pmc: PMC6350173
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Clopidogrel
A74586SNO7
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
457-468Déclaration de conflit d'intérêts
Conflict-of-interest statement: There are no conflicts of interest.
Références
Gastric Cancer. 2000 Dec;3(4):219-225
pubmed: 11984739
JAMA. 2005 May 4;293(17):2126-30
pubmed: 15870416
Circulation. 2007 Feb 13;115(6):813-8
pubmed: 17224480
Am J Gastroenterol. 2007 Aug;102(8):1610-6
pubmed: 17403076
Endoscopy. 2008 Mar;40(3):179-83
pubmed: 18322872
Gastrointest Endosc. 2009 Jun;69(7):1228-35
pubmed: 19249769
J Gastroenterol. 2010;45(1):30-6
pubmed: 19760133
Digestion. 2009;80(3):173-81
pubmed: 19776581
Gastrointest Endosc. 2009 Dec;70(6):1060-70
pubmed: 19889407
Gastrointest Endosc. 2010 Feb;71(2):241-8
pubmed: 19922919
J Am Coll Cardiol. 2009 Dec 1;54(23):2205-41
pubmed: 19942100
Surg Endosc. 2011 Jan;25(1):98-107
pubmed: 20549245
World J Gastroenterol. 2010 Jun 21;16(23):2913-7
pubmed: 20556838
Dig Endosc. 2011 Oct;23(4):290-5
pubmed: 21951088
Gastrointest Endosc. 2011 Dec;74(6):1268-75
pubmed: 22015001
J Gastroenterol Hepatol. 2012 May;27(5):907-12
pubmed: 22142449
Endoscopy. 2012 Feb;44(2):114-21
pubmed: 22271021
Gastrointest Endosc. 2012 Apr;75(4):719-27
pubmed: 22317881
Scand J Gastroenterol. 2012 Sep;47(8-9):1108-14
pubmed: 22783937
Gut Liver. 2012 Jul;6(3):316-20
pubmed: 22844558
Gastrointest Endosc. 2013 Sep;78(3):476-83
pubmed: 23622974
BMC Gastroenterol. 2013 Sep 06;13:136
pubmed: 24010587
Gastric Cancer. 2014;17(3):489-96
pubmed: 24142107
Dig Endosc. 2014 Jan;26(1):1-14
pubmed: 24215155
BMC Gastroenterol. 2014 Oct 03;14:172
pubmed: 25280756
Endoscopy. 2015 Jul;47(7):632-7
pubmed: 25590184
Endosc Int Open. 2015 Feb;3(1):E31-8
pubmed: 26134769
Gastrointest Endosc. 2016 Jan;83(1):3-16
pubmed: 26621548
Endoscopy. 2016 Apr;48(4):385-402
pubmed: 26890676
World J Gastrointest Endosc. 2016 Apr 10;8(7):349-56
pubmed: 27076874
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Dig Endosc. 2017 Sep;29(6):686-694
pubmed: 28295638
Dig Endosc. 2017 Sep;29(6):676-677
pubmed: 28459505
Endosc Int Open. 2017 May;5(5):E348-E353
pubmed: 28484736